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Introduction
The incidence of osteoporotic fractures in postmenopausal women is very high. In the US and UK, approximately 40-50% of all women will suffer at least one osteoporotic fracture during their lifetime (Table 1 ) [1] .
Also in men, osteoporosis is prevalent. In USA, 13% of all men will suffer at least one of osteoporotic fracture, while in the UK this figure is about 20%. But the problem is about to increase even further since the proportion of senior citizens is increasing in many populations. In Denmark for example, the number of persons aged 65 years or more will increase by approximately 50% during the next 40 years.
Osteoporosis is defined as a disease of "decreased bone mass and deteriorated bone structure to such an extent that bone strength is decreased and the risk of fracture increased" [2] . Peak bone mass (the maximum bone mass attained during adolescent years) and post-menopausal as well as age-related bone loss are important concepts to understand the pathogenesis of this disease.
Genetic factors and osteoporosis
Twin and family studies have demonstrated that the peak bone mass is to a large extend genetically pro- (Fig. 1) . Recently, the same polymorphism has been linked to peak bone mass in men [13] . Based on our current knowledge, only rare cases of osteoporosis are monogenetic disorders. Interaction between many genes seems, however, to be part of the pathogenesis of the common forms of post-menopausal and age-related osteoporosis. Further understanding of these interactions may increase our ability to predict fracture risk and bone loss. 
Post-menopausal decline in estrogen levels

Smoking and other life-style factors
An often neglected risk factor for osteoporosis is 
Pharmacological treatment of osteoporosis
Primary prevention is defined as efforts to increase bone mass or prevent fractures in the general population.
Secondary and tertiary prevention are the treatment of patients with osteoporosis and manifested osteoporosis (i.e. prevalent fractures), respectively. 
Vitamin-D
Estrogen and selective estrogen receptor modifiers
Bisphosphonates
Bisphosphonates are currently the most widely used anti-osteoporotic agents world-wide and numerous studies have demonstrated their ability to prevent bone loss.
Etidronate [26, 27] , alendronate[28~31], risedronate [32, 33] , ibandronate [34] , and pamidronate [35] have been demons- This leads to increased BMD and may probably explain some of the anti-fracture efficacy of these drugs.
Parathyroid hormone-like drugs
Recently, parathyroid hormone (PTH(1-34)) was approved for use in US and Europe. PTH(1-34) or teriparatide is synthesized by genetically modified E. Coli, and this drug has dramatic anabolic effects on bone mass. It increases BMD in the lumbar spine and hip by 9.7% and 2.6%, respectively, after 18 months. This translates into a pronounced risk reduction considering vertebral fractures (65%) and appendicular fractures (35%) [36] . In a randomized comparison of teriparatide and alendronate, BMD in the spine increased in the alendronate group during one and half year by about 4-5%. In contrast, a 10% increase was seen in the teriparatide group. This difference is even more pronounced in the trabecular bone within the vertebral bodies where alendronate increased BMD about 4 to 5% while teriparatide increased this parameter by almost 18% [37] . Teriparatide increases bone remodelling and may initially lead to an apparent decrease in bone mass due to decreased degree of mineralization and expansion of the remodelling space. With time, however, bone dimensions, cortical thickness, and the number of trabecular elements increase leading to increasing bone strength.
Strontium ranelate
Strontium ranelate is a new drug recently registered for clinical use in Europe. The organic part of the molecule (ranelic acid) is biologically inert but facilitates absorption and increases bioavailability of strontium. This drug seems to have both anabolic and anti-resorptive effects and constitutes a new class of "dual action bone agents".
Strontium ranelate enhanced preosteoblastic cell replication and increased collagen synthesis by osteoblast [38] . Also, mature osteoblasts are stimulated to produce more non-collagenous protein as well as collagen. In different in vivo model systems, strontium ranelate has been demonstrated to decrease bone resorption [39] .
Strontium ranelate has been tested in a comprehensive clinical program. The pivotal phase-III studies took places in 75 centers in 12 countries, including Denmark, and the compound is currently been tested in Korea and other Asian countries. During the "First study", a run-in period of 2 weeks to 6 months, vitamin-D status was assessed and supplementation administered with both vitamin-D and calcium in order to overcome any deficiencies (Fig. 3 ). In both SOTI and TROPOS, BMD of the lumbar spine increased significantly by 14% (Fig. 4 ). Strontium has a higher atomic number that calcium and thus attenuates X-rays more than calcium. As a consequence, approximately 50% of the increase in BMD may be due to the strontium content in the bone perse. Similarly, BMD of the femoral neck increased by 8% compared with placebo.
In clinical terms, treatment decreased the incidence of vertebral fractures by 49% during the first year of treatment and by 41% during the three year of treatment ( Fig. 5) . This corresponds to a "number-needed-to-treat" of only 9 to avert one vertebral fracture. Post-hoc analysis of the pooled data from SOTI and TROPOS demonstrated a risk reduction of 40% was found in clinical vertebral fractures. Also, a similar risk reduction was found in patients with and without prevalent fractures at baseline, in patients more than 80 years old, and in patients with osteopenia. Treatment also decreased the risk of peripheral fractures by 16% during the 3-year period in the intention-to-treat analysis; i.e. this analysis included all patients. In the per-protocol analysis (i.e. restricting the analysis to patients complying with the protocol) the effect was even more impressive -a 33% reduction in the risk of peripheral fractures. Strontium ranelate also decreased the risk of hip fractures in predefined high-risk group (i.e. patients above the age of 75 years and with a T-score ≤ -3) by 36% (Fig. 6 ).
It has been our experience throughout the studies and in 
Questions and answers:
Question. Are you sure that strontium ranelate stimulates osteoblast formation? You showed no data on the mechanism of action on the molecular level.
Answer. Data have shown that strontium interacts with calcium receptor and that this may be involved in the increase in bone formation seen in vitro. But, the exact molecular mechanisms of action are currently unknown.
Further work clearly has to be done on that issue.
Question. What is the therapeutic window for strontium ranelate in osteoporosis?
Answer. The dose-finding study applied doses of 0.5, 1, and 2 grams/day. The most pronounced effect was found with the highest dosage and this was chosen for further development. In animal studies, very high doses may lead to osteomalacia, however, no cases of osteomalacia were seen in bone biopsies in the human studies.
Question. Do you use estrogen in the treatment of osteoporosis?
Answer. We still use estrogen in young (i.e. below the age of 50 years) post-menopausal women. In these women, we usually advise the use of estrogen until the age of 50 years. In women aged 50 years or more, we are now reluctant to apply long-term treatment. The advice from the Danish Health Board is to keep treatment as short as possible (i.e. less than 3 years), to use the lowest possible dosage, and to interrupt treatment every 1-2 years to evaluate climacteric symptoms. Follow-up on the WHI study, however, have just reported that a significant number of the patients is back on estrogen after a period of interruption. This demonstrates that many women have severe climacteric symptoms and feel that the benefits of treatment outweigh the risks. We are now in the position to communicate the exact risk associated with such treatment and let the patients decide.
Question. You showed excellent data on strontium;
BMD increased remarkably and fracture rate decreased.
Do you think that strontium improves bone quality, and how does strontium ranelate compare with bisphosphonates in that respect?
Answer. Bisphosphonates act primarily by increasing mean age of bone and decreasing bone resorption and remodeling spaces (the number of open osteoclastic lacunae). They are, however, not anabolic. Strontium acts differently; it decreases bone resorption, but not to the same extend as bisphosphonates. Biopsy data show that strontium increases cortical thickness and also increases mineral appositional rate. So it seems that strontium has dual action; both anti-resorptive and anabolic effects. As to the idea of bone quality, this is difficult to assess. Hopefully, we will be able to do this in the future. 
